Search alternatives:
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
weaker decrease » teer decrease (Expand Search), water decreases (Expand Search)
significant linear » significant clinical (Expand Search), significant gender (Expand Search), significant level (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
weaker decrease » teer decrease (Expand Search), water decreases (Expand Search)
-
2301
Image 5_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff
Published 2025“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”
-
2302
Image 3_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff
Published 2025“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”
-
2303
Image 4_Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway.tiff
Published 2025“…Notably, E2-induced increased B cell antibody responses conferred greater protection from HSV-2 challenge compared to placebo mice as evidenced by 2–3 logs decreased viral titers in the vaginal tract and 20% mice with genital pathology compared to 80% in placebo group, indicating better protection in E2-treated mice. …”
-
2304
<b>Feeding Ecology of the Critically Endangered </b><b><i>Gobio insuyanus </i></b><b>(Gobionidae)</b>
Published 2025“…Dietary diversity was higher in the stream, potentially reflecting its greater habitat complexity, but decreased in both habitats in autumn, suggesting a seasonal decline in prey availability. …”
-
2305
Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2306
Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2307
Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2308
Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2309
Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2310
Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2311
Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2312
Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2313
Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2314
Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2315
Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2316
Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2317
Identifying cyst initiation candidate genes through mRNA sequencing <i>Pkd2</i> mouse kidneys at pre-cystic and early cystic time points.
Published 2024“…Details of each study can be found in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1011510#pgen.1011510.t002" target="_blank">Table 2</a>. There is significant correlation between P6 and each group by simple linear regression analysis (two-tailed p-values: P10, p<0.0001; ZS, p<0.0001; KP2, p = 0.0014; KP3, p = 0.0016; KP6, p = 0.0012).…”
-
2318
Boxplots showing the differences in miR-21-5p and miR-16-5p levels across increasing AKI severity based on Kidney Disease: Improving Global Outcomes (KDIGO) grades.
Published 2025“…<p>Elevated miR-21-5p levels and decreased miR-16-5p levels correspond to greater AKI severity. …”
-
2319
Rising mercury consumption from blue foods in China balanced by a shift to lower-mercury choices
Published 2025“…Results show that despite per capita THg consumption rose gradually due to rising blue food consumption, there was a national shift toward low-THg blue foods driven by increased shrimp and decreased high-THg fish consumption. Coastal regions exhibited the highest THg consumption due to greater blue food consumption while Northwest China displayed high-THg preferences with low overall consumption. …”
-
2320
Supplementary file 1_Tapered fiber probe-based optical cardiac pacemaker.docx
Published 2025“…Meanwhile, anatomical mapping demonstrated 1.7-fold greater photosensitivity in sinoatrial regions compared to ventricular myocardium. …”